Overview / Abstract: |
Age-related macular degeneration (AMD) is the leading cause of legal blindness in adults over age 50, but the development of agents that target vascular endothelial growth factor (VEGF) has revolutionized its treatment. There are currently two FDA-approved agents (ranibizumab and aflibercept) and one off-label anti-VEGF agent (bevacizumab) being used to treat patients with AMD, and data from emerging anti-VEGF agents have also demonstrated efficacy in improving visual acuity. However, step therapy requirements pose significant barriers to patient access to approved anti-VEGF therapies. The first part of this CME Outfitters Snack series on overcoming the challenges of prior authorization when treating patients with AMD features expert faculty discussing how to implement patient-centric care models that incorporate shared decision-making, which is imperative to educating patients on the benefits and risks of FDA-approved and off-label agents for the treatment of AMD. |
Expiration |
Nov 21, 2020 |
Discipline(s) |
Nurse Practitioner , Nursing CNE, Optometry / Ophthalmology CE, Pharmacy CPE, Physician CME, Physician Assistant CME |
Format |
Online, Webinar / Webcast / Video |
Credits / Hours |
0.5 AMA PRA Category 1 Credit(s)™/contact hours/CEUs |
Accreditation |
ACCME, ABO, AAPA, ACPE, AANP, RCPSC |
Presenters / Authors / Faculty |
Darius M. Moshfeghi, MD Derek van Amerongen, MD, MS |
Sponsors / Supporters / Grant Providers |
This activity is supported by an independent medical education grant from Regeneron Pharmaceuticals, Inc. |
Keywords / Search Terms |
CME Outfitters, LLC AMD, age-related macular degeneration, optometry, ophthalmology, eye disease, optical Free CE CME |